AzTrials
AzTrials

Acute AppendicitisMAPPACNCT03257423

Acute Appendicitis and Microbiota - Etiology of Appendicitis and Antibiotic Therapy Effects

A study testing Ertapenem followed by levofloxacin and metronidazole, Moxifloxacin and Appendectomy in people with Acute Appendicitis, run by Turku University Hospital at 1 site in Finland.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Appendicectomy has been the treatment of acute appendicitis for over a hundred years. Appendicectomy, however, includes operative and postoperative risks despite being a routine procedure. Read more about this study

Who is it for?
Ages 18 to 60 years
Conditions the study is for
Acute Appendicitis
What is being tested?
Ertapenem followed by levofloxacin and metronidazole, Moxifloxacin and Appendectomy
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
200 participants
Where
1 siteFinland
Study dates
4 Apr 2017to 31 Dec 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Age 18-60 years
  • CT confirmed uncomplicated or complicated acute appendicitis
  • Ability to give consent to participate in the study

Who cannot join

  • Age under 18 years or over 60 years
  • Pregnancy or lactation
  • Allergy to contrast media or iodine
  • Allergy or contraindication to antibiotic therapy
  • Renal insufficiency
  • Metformin medication
  • Severe systemic illness (for example malignancy, medical condition requiring immunosuppressant medication)
  • Inability to co-operate and give informed consent

Trial locations and contacts

1 site in 1 country.

Finland1 site
  • Turku University Hospital

    Turku

Other trials in Finland

About this study

Official title: Acute Appendicitis and Microbiota - Ethology of Appendicitis and Effects of the Antimicrobial Treatment - The MAPPAC (Microbiology Appendicitis Acuta) Trial

Appendicectomy has been the treatment of acute appendicitis for over a hundred years. Appendicectomy, however, includes operative and postoperative risks despite being a routine procedure. Several studies have proved promising results of the safety and efficiency of antibiotics in the treatment of acute uncomplicated appendicitis. The previous APPAC study by the investigators, published in 2015 in the Journal of American Medical Association, also proved promising results with 73% of patients with uncomplicated appendicitis treated successfully with antibiotics. None of the patients initially treated with antibiotics that later had appendectomy had major complications. The results of the APPAC trial suggest that CT proven uncomplicated acute appendicitis is not a surgical emergency and antibiotic therapy is a safe first-line treatment option. Reducing unnecessary appendectomies has also been shown to lead to significant economic savings. On the other hand, antibiotic therapies have been shown to have an effect on the normal gut microbiota and are considered an increasing global health threat underlining the importance of evaluating both short- and long-term effects of the antimicrobial treatment in old and new indications.

The aims of this randomized prospective study are:

  1. To evaluate the possible role and differences in the microbiological etiology of complicated and uncomplicated appendicitis.
  2. To determine the effects of both antibiotic and placebo treatment on the composition of gut microbiota, and to evaluate how it recovers after the appendicitis-related antimicrobial treatment (AMT)
  3. To evaluate the effects of the duration of the hospital stay on the AMR reservoir of the gut microbiota.
Read the detailed description

Appendectomy has been the treatment of acute appendicitis for over a hundred years. Appendicectomy, however, includes operative and postoperative risks despite being a routine procedure. Several studies have proved promising results of the safety and efficiency of antibiotics in the treatment of acute uncomplicated appendicitis. The previous APPAC study by the investigators, published in 2015 in the Journal of American Medical Association, also proved promising results with 73% of patients with uncomplicated appendicitis treated successfully with antibiotics. None of the patients initially treated with antibiotics that later had appendectomy had major complications. The results of the APPAC trial suggest that CT proven uncomplicated acute appendicitis is not a surgical emergency and antibiotic therapy is a safe first-line treatment option. Reducing unnecessary appendectomies has also been shown to lead to significant economic savings. On the other hand, antibiotic therapies have been shown to have an effect on the normal gut microbiota.

Gut microbiota is an extremely complex ecosystem with both high bacterial density and diversity. Recent scientific evidence emphasizes that the symbiosis between the host and the balanced gut microbiota supports good health, and contributes to various biochemical and metabolic functions occurring in host's body. The possible role of the somehow distorted gut microbiota composition in addition to its metabolites in the etiopathogenesis of many diseases such as allergy, inflammatory bowel disease, type 1 diabetes and obesity related disorders, has been recently proposed. Further, detected alterations and perturbations both in the gut microbiota composition and functionality have been linked to the development of various malignancies such as colorectal cancer, gastric cancer and hepatocellular carcinoma. To date, the role of the microbes and especially the members of the commensal microbiota with their structural compartments and metabolites in the pathogenesis and etiology of appendicitis have not been clarified in detail, despite the recent knowledge that uncomplicated acute appendicitis could be treated by antibiotic treatments alone. Further, there is only limited amount of evidence on the appendix microbial composition in humans.

Microbial overgrowth has been speculated to serve as a secondary consequence in appendicitis. However, recent accumulating evidence suggests that primary bacterial infection may actually be an initiating event in the pathogenesis of the disease. Interestingly, it has been postulated that the appendix could serve as a microbial reservoir for repopulating the gastrointestinal tract in times of necessity thus gut microbiota may act as a source for these pathogenic intruders. Further it has been reported that certain members of the gram negative Fusobacteria especially F. nucleatum and necrophorum are present in most appendicitis samples.

Additionally, antimicrobial resistance (AMR) is considered an increasing global threat. According to the WHO (World Health Organisation), in 2050s more people will be killed by AMR bacteria than by all cancers.The use of antimicrobials in humans and especially in animal health care and production industry are the major causes of increasing AMR worldwide; the prudent use of antimicrobials is essential to prevent increasing AMR. Antimicrobials are known to decrease the gut microbiota diversity, richness and species variation and cause the perturbation of its overall balance and even a short-term antimicrobial treatment has a long-term impact on its composition underlining the importance of evaluating both short- and long-term effects of the antimicrobial treatment in old and new indications.

The aims of this randomized prospective study are:

  1. To evaluate the possible role and differences in the microbiological etiology of complicated and uncomplicated appendicitis. The bacterial composition of the complicated appendix will be compared to the gut microbiota composition determined from the fecal sample collected from the same individual. Additionally, these results will be compared to the gut microbiota composition of patients with uncomplicated acute appendicitis.
  2. To determine the effects of both antibiotic and placebo treatment on the composition of gut microbiota, and to evaluate how it recovers after the appendicitis-related antimicrobial treatment (AMT). The bacterial composition and AMR reservoir of the gut microbiota will be evaluated both pre and post treatment in patients receiving antibiotic or placebo treatment for uncomplicated acute appendicitis. Additionally, the recovery of gut microbiota composition and disappearance of AMR will be evaluated. We will compare two variations (i.v.and p.o.) of antibiotic treatment with the placebo treatment.
  3. To evaluate the effects of the duration of the hospital stay on the AMR reservoir of the gut microbiota. According to the study protocols of the APPAC II and III trials, patients will spend either 1 or 3 days in the hospital in order to receive treatment before continuing the selected treatment at home. We will evaluate the effects of length of stay on the AMR reservoir of gut microbiota as well as evaluating if and when possible colonization occurs.
Being tested
Ertapenem followed by levofloxacin and metronidazole, Moxifloxacin, Appendectomy, Placebo
Keywords
Uncomplicated acute appendicitis, Complicated acute appendicitis, Antibiotic therapy, Microbiological etiology
Medical subject headings
Appendicitis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Ertapenem followed by levofloxacin and metronidazoleDrug

    Ertapenem 1 g i.v. daily for either 2 days (MAPPAC + APPAC II patients) or 3 days (MAPPAC + APPAC III) followed by p.o. levofloxacin 500 mg x 1 + metronidazole 500 mg x 3 for either 5 days (APPAC II + MAPPAC) or 4 days (APPAC III + MAPPAC)

  • MoxifloxacinDrug

    Moxifloxacin 400 mg once a day for seven days (APPAC II + MAPPAC)

  • AppendectomyProcedure or surgery

    Primarily laparoscopic appendectomy for either complicated acute appendicitis or uncomplicated acute appendicitis (refusing to participate in APPAC II or III trials or recurrent acute appendicitis).

  • PlaceboOther

    Placebo i.v. once a day for three days (APPAC III + MAPPAC) followed by placebo capsules three times a day for four days.

Study groups in NCT03257423
Study groupRoleWhat they receive
I.v. + p.o. antibiotics (APPAC II)Active comparatorPatients in this group recruited also in APPAC II trial will receive i.v. antibiotics (ertapenem 1 g twice per day) for 2 days followed by p.o. antibiotics (levofloxacin 500 mg x 1 and metronidazole 500 mg x 3) for 5 days, for a total treatment duration of 7 days. From these patients, rectal swab samples will be collected at day 0 (before treatment) and day 1 (after beginning of treatment), serum sample before treatment initiation.
Receives: Drug: Ertapenem followed by levofloxacin and metronidazole
P.o. moxifloxacin (APPAC II)Active comparatorPatients in this group recruited also in APPAC II trial will receive p.o. antibiotics for a total of 7 days, moxifloxacin 400 mg once per day. From these patients, rectal swab samples of faces will be collected at two time points, day 0 (before treatment) and day 1 (after beginning of treatment), serum sample before treatment initiation.
Receives: Drug: Moxifloxacin
Placebo treatment (APPAC III)Placebo comparatorPatients in this group recruited also in APPAC III trial will receive i.v. placebo 3 times per day for 3 days followed by p.o. placebo 3 times per day for 4 additional days. From these patients rectal swab samples will be collected twice during the stay at the research hospital (time points 0 and 1 or 3 d) and three times at home (follow-up at one week, six months and one year). Serum samples are taken prior to treatment initiation and at 10 days after the treatment initiation.
Receives: Other: Placebo
Surgery (complicated appendicitis)OtherPatients in this group will undergo appendectomy and are recruited only in the MAPPAC trial. Rectal swab samples and biopsies from the removed appendix will be collected from these patients.
Receives: Procedure: Appendectomy
Surgery (uncomplicated appendicitis)OtherPatients in this group will undergo appendectomy either after refusing to participate in the APPAC II or APPAC III trials or after presenting with recurrent appendicitis after antibiotic or placebo therapy. Rectal swab samples of faces and biopsies from the removed appendix will be collected from these patients.
Receives: Procedure: Appendectomy
I.v. + p.o. antibiotics (APPAC III)Active comparatorPatients in this group recruited also in APPAC III trial will receive i.v. antibiotics (ertapenem 1 g twice per day) for 3 days followed by p.o. antibiotics (levofloxacin 500 mg x 1 and metronidazole 500 mg x 3) for 4 days, for a total treatment duration of 7 days. From these patients rectal swab samples will be collected twice during the stay at the research hospital (time points 0 and 1 or 3 d) and three times at home (follow-up at one week, six months and one year). Serum samples are taken prior to treatment initiation and at 10 days after the treatment initiation.
Receives: Drug: Ertapenem followed by levofloxacin and metronidazole

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Microbiology in the etiology of acute appendicitis

    Differences in the microbiological etiology of complicated and uncomplicated appendicitis

    Measured: 1 day

Secondary outcomes (2)
  1. Effects of antimicrobial treatment on gut microbiota

    Determining the effects of both antibiotic and placebo treatment on the composition of gut microbiota, and to evaluate how it recovers after the appendicitis-related antimicrobial treatment evaluated by rectal swabs pre- and post treatment

    Measured: 1 year

  2. Effects of hospital stay duration on the AMR reservoir of the gut microbiota

    The effect of length of hospital stay (days) on the AMR reservoir of gut microbiota and colonization occurrence evaluated by analysing rectal swabs microbiota pre- and post-treatment at 0, 1 and 3 days.

    Measured: 3 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Aug 2017
  2. Study start4 Apr 2017
  3. Primary completion31 Dec 2022 (estimated)
  4. Study completion31 Dec 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Non-randomised
Intervention model
Parallel groups
Model description
Patients are enrolled in conjuction with APPAC II (NCT03236961) and APPAC III (NCT 03234296) trials, all patients with uncomplicated or complicated acute appendicitis are evaluated for MAPPAC enrollment. MAPPAC study groups: complicated acute appendicitis (samples: rectal swabs, serum, removed appendix), APPAC II patients in two groups according to APPAC II randomized antibiotic therapy (uncomplicated acute appendicitis, samples: rectal swabs, serum and in cases of antibiotic treatment failure or appendicitis recurrence also removed appendix), APPAC III patients in two groups according to APPAC III randomized group of antibiotc or placebo therapy (uncomplicated acute appendicitis, samples: rectal swabs, serum and in cases of antibiotic or placebo treatment failure or appendicitis recurrence also removed appendix), and patients with uncomplicated acute appendicitis declining to participate in APPAC II or III trials undergoing appendectomy
Masking
None (open label)
Enrolment
200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03257423
Sponsor's protocol ID
MAPPAC
Acronym
MAPPAC
Status last verified
Nov 2020
First submitted
2 Aug 2017
Last updated
10 Nov 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Han T, Borman T, Vanhatalo S, Lahti L, Loyttyniemi E, Hurme S, Munukka E, Kallonen T, Hakanen A, Hollmen M, Salminen P. Uncomplicated and Complicated Acute Appendicitis Induce Different Cytokine Patterns. APMIS. 2026 Feb;134(2):e70168. doi: 10.1111/apm.70168.

    PubMed 41711118
  • Vanhatalo S, Makila E, Hakanen AJ, Munukka E, Salonen J, Saarinen T, Gronroos J, Sippola S, Salminen P. Appendicolith classification: physical and chemical properties of appendicoliths in patients with CT diagnosed acute appendicitis - a prospective cohort study. BMJ Open Gastroenterol. 2024 Aug 19;11(1):e001403. doi: 10.1136/bmjgast-2024-001403.

    PubMed 39160081
  • Vanhatalo S, Munukka E, Kallonen T, Sippola S, Gronroos J, Haijanen J, Hakanen AJ, Salminen P. Appendiceal microbiome in uncomplicated and complicated acute appendicitis: A prospective cohort study. PLoS One. 2022 Oct 14;17(10):e0276007. doi: 10.1371/journal.pone.0276007. eCollection 2022.

    PubMed 36240181
  • Vanhatalo S, Munukka E, Sippola S, Jalkanen S, Gronroos J, Marttila H, Eerola E, Hurme S, Hakanen AJ, Salminen P; APPAC collaborative study group. Prospective multicentre cohort trial on acute appendicitis and microbiota, aetiology and effects of antimicrobial treatment: study protocol for the MAPPAC (Microbiology APPendicitis ACuta) trial. BMJ Open. 2019 Sep 6;9(9):e031137. doi: 10.1136/bmjopen-2019-031137.

    PubMed 31494621

Questions about this trial

What is this clinical trial studying?

A study testing Ertapenem followed by levofloxacin and metronidazole, Moxifloxacin and Appendectomy in people with Acute Appendicitis, run by Turku University Hospital at 1 site in Finland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 10 Nov 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Finland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Microbiology in the etiology of acute appendicitis (time frame: 1 day). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03257423, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Nov 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in